CirrhosisEUS-VEINNCT07703540
Inferior Vena Cava Pressure as Alternative to Hepatic Venous Pressure for EUS-guided Portal Pressure Gradient Measurement
An observational study of Cirrhosis and Liver Disease Chronic, run by University Hospital Muenster at 1 site in Germany.
Trial summary
This study investigates a new, simplified approach to measuring blood pressure within the liver (portal hypertension) using Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement (EUS-PPG). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cirrhosis, Liver Disease Chronic, Portal Hypertension
- What is being tested?
- HVP-PPG and IVCP-PPG
- How many people
- 40 participants
- Where
- 1 siteGermany
- Study dates
- 1 Feb 2026to 15 May 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of consecutive adult patients ($\ge18$ years) undergoing a clinically indicated EUS-PPG measurement (e.g., for liver disease evaluation, fibrosis staging, or portal hypertension assessment).
Who may be able to join
- Consecutive adult patients (≥18 years) undergoing clinically indicated EUS-guided portal pressure gradient measurement
Who cannot join
- severe coagulopathy (INR >2.0), thrombocytopenia (<50,000/µL)
- large-volume ascites
- gastric varices precluding safe vascular puncture
- known hepatic vein thrombosis or Budd-Chiari syndrome
- altered IVC anatomy such as patients after liver transplantation with piggy-back anastomosis
- contraindication to upper gastrointestinal endoscopy or sedation
- pregnancy
Trial locations and contacts
1 site in 1 country.
Germany1 site
University Hospital Muenster
Münster, North Rhine-Westphalia, 48149
About this study
This study investigates a new, simplified approach to measuring blood pressure within the liver (portal hypertension) using Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement (EUS-PPG). While this minimally invasive method traditionally relies on a hepatic vein as the baseline reference point, advanced liver scarring can make these veins twisted and highly difficult to access. To address this challenge, our study evaluates the Inferior Vena Cava (IVC)-the body's largest main vein-as an alternative reference site. Currently, it remains scientifically unproven whether the inferior vena cava or the hepatic vein provides the more reliable and accurate pressure reading for calculation, as anatomical distortion from cirrhosis can affect both areas differently. By measuring and comparing both venous compartments during a single, clinically scheduled endoscopy session, this study aims to determine if the pressures are truly interchangeable. Ultimately, this research will clarify which vessel serves as the optimal reference point, helping to establish a safer, more reliable diagnostic standard for patients with complex vascular anatomy.
- Conditions
- Cirrhosis, Liver Disease Chronic, Portal Hypertension
- Being tested
- HVP-PPG and IVCP-PPG
- Keywords
- EUS-PPG, EUS, Portal hypertension, Portal vein pressure, Clinically significant portal hypertension (CSPH), Inferior vena cava pressure, Endoscopic ultrasound-guided portal pressure gradient
- Medical subject headings
- Fibrosis, Hypertension, Portal
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HVP-PPG and IVCP-PPGDiagnostic test
During a clinically indicated endoscopic ultrasound (EUS), patients undergo portal pressure gradient (PPG) measurement using a linear-array echoendoscope and a dedicated needle system (22G or 25G). The intervention utilizes a transgastric approach to sequentially measure pressures in three vessels: a left intrahepatic portal vein branch, a hepatic vein, and the inferior vena cava (IVC). The IVC is safely punctured through a window covered by liver tissue. Pressures are measured in triplicate per vessel. This protocol uniquely calculates two distinct gradients within the same procedural session: HVP-PPG: Calculated as the mean portal vein pressure minus the mean hepatic vein pressure (HVP). IVCP-PPG: Calculated as the mean portal vein pressure minus the mean inferior vena cava pressure (IVCP).
| Study group | Role | What they receive |
|---|---|---|
| HVP-PPG and IVCP-PPG | Patients undergoing both measurements (HVP-PPG and IVCP-PPG) Receives: Diagnostic Test: HVP-PPG and IVCP-PPG |
What is being measured
The primary outcome is the main question the study is designed to answer.
Agreement between mean hepatic vein pressure and mean inferior vena cava pressure measured during the same EUS-PPG session
Based on prior reproducibility data for EUS-guided portal pressure measurements, a predefined absolute difference of >1 mmHg between HVP and IVCP was considered clinically relevant. Differences ≤1 mmHg after rounding to the nearest whole mmHg were considered hemodynamically equivalent, reflecting clinical pressure reporting practice.
Measured: Intraprocedural
Secondary outcomes (5)
Correlation between HVP and IVCP, Bland-Altman analysis of agreement and systematic bias
Measured: Intraprocedural measurement
Agreement between PPG-HV and PPG-IVC
Measured: Intraprocedural measurement
Reclassification across clinically significant portal hypertension thresholds (≥10 mmHg)
Measured: Intraprocedural measurement
Intraprocedural variability of triplicate measurements
Measured: Intraprocedural measurement
Procedural adverse events
Measured: Up to 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start1 Feb 2026
- Primary completion30 Apr 2026
- Study completion15 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (19)Papers the sponsor has linked to this study.
- Other trials for CirrhosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital Muenster
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Dr. Michael Praktiknjo, University Hospital Muenster
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07703540
- Sponsor's protocol ID
- MSPPG1
- Acronym
- EUS-VEIN
- Status last verified
- Feb 2026
- First submitted
- 8 Jul 2026
- Last updated
- 14 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Santopaolo F, Giuli L, Tripodi G, Pallozzi M, Ponziani FR, Annicchiarico BE, Rizzatti G, Contegiacomo A, Posa A, Iezzi R, Talerico R, Gasbarrini A, Larghi A. Prognostic Role of Endoscopic Ultrasound Guided Direct Portal Pressure Gradient Measurement in Porto-Sinusoidal Vascular Disorder. Liver Int. 2025 May;45(5):e70096. doi: 10.1111/liv.70096.
PubMed 40251984Benmassaoud A, Bessissow A, Samoukovic G, Wong P, Zhao X, Deschenes M, Sebastiani G, Cabrera T, Valenti D, Boucher LM, Pelage JP, Muchantef K, Cardenas A, Givis MA, White S, Bousquet-Dion G, Waked C, Jacques J, Rahme E, Geraci O, Martel M, Barkun A, Maedler-Kron C, Chen YI. EUS-Guided Liver Biopsy and Portal Pressure Measurement Compared With a Transjugular Approach: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2026 Jun;24(6):1601-1610. doi: 10.1016/j.cgh.2025.09.025. Epub 2025 Oct 3.
PubMed 41046961Praktiknjo M, Farouk N, Wang Z, Stadtmann J, van de Loo D, Kimmann M, Gunia C, Meier JA, Uschner FE, Peiffer KH, Laleman W, Trebicka J, Braden B. Same Session Validation of a Custom-Built 22G With the Commercial 25G System for EUS-Guided Portal Pressure Gradient Measurement. United European Gastroenterol J. 2026 Mar;14(2):e70194. doi: 10.1002/ueg2.70194.
PubMed 41748429Zhang W, Peng C, Zhang S, Huang S, Shen S, Xu G, Zhang F, Xiao J, Zhang M, Zhuge Y, Wang L, Zou X, Lv Y. EUS-guided portal pressure gradient measurement in patients with acute or subacute portal hypertension. Gastrointest Endosc. 2021 Mar;93(3):565-572. doi: 10.1016/j.gie.2020.06.065. Epub 2020 Jun 29.
PubMed 32615178Rossle M, Blanke P, Fritz B, Schultheiss M, Bettinger D. Free Hepatic Vein Pressure Is Not Useful to Calculate the Portal Pressure Gradient in Cirrhosis: A Morphologic and Hemodynamic Study. J Vasc Interv Radiol. 2016 Aug;27(8):1130-7. doi: 10.1016/j.jvir.2016.03.028. Epub 2016 Jun 7.
PubMed 27212121Silva-Junior G, Baiges A, Turon F, Torres F, Hernandez-Gea V, Bosch J, Garcia-Pagan JC. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology. 2015 Nov;62(5):1584-92. doi: 10.1002/hep.28031. Epub 2015 Sep 30.
PubMed 26238376Rodrigues SG, Delgado MG, Stirnimann G, Berzigotti A, Bosch J. Hepatic Venous Pressure Gradient: Measurement and Pitfalls. Clin Liver Dis. 2024 Aug;28(3):383-400. doi: 10.1016/j.cld.2024.03.009. Epub 2024 May 1.
PubMed 38945633Groszmann RJ, Glickman M, Blei AT, Storer E, Conn HO. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology. 1979 Feb;76(2):253-8.
PubMed 759258Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. J Vis Exp. 2020 Jun 18;(160). doi: 10.3791/58819.
PubMed 32628153Singla N, Shantan V, Saraswat A, Singh AP. Advances in portal pressure measurement: Endoscopic techniques, challenges, and implications for liver transplantation. World J Hepatol. 2025 Aug 27;17(8):107679. doi: 10.4254/wjh.v17.i8.107679.
PubMed 40901597Dhindsa BS, Tun KM, Fiedler A, Deliwala S, Saghir SM, Scholten K, Ramai D, Girotra M, Chandan S, Dhaliwal A, Bhat I, Singh S, Adler DG. Endoscopic ultrasound-guided portal pressure gradient measurement: a systematic review and meta-analysis. Ann Gastroenterol. 2024 May-Jun;37(3):356-361. doi: 10.20524/aog.2024.0882. Epub 2024 Apr 29.
PubMed 38779643Martinez-Moreno B, Martinez Martinez J, Herrera I, Guilabert L, Rodriguez-Soler M, Bellot P, Miralles C, Pascual S, Irurzun J, Zapater P, Palazon-Azorin JM, Gil Guillen V, Jover R, Aparicio JR. Correlation of endoscopic ultrasound-guided portal pressure gradient measurements with hepatic venous pressure gradient: a prospective study. Endoscopy. 2025 Jan;57(1):62-67. doi: 10.1055/a-2369-0759. Epub 2024 Jul 18.
PubMed 39025130Vanderschueren E, Laleman W, Bonne L, Maleux G, Wagner DR, Yeh C, Calvo A, Sendino O, Gines A, Baiges A, Bruno MJ, Garcia-Pagan JC, van der Merwe S. Endoscopic ultrasound-guided portosystemic pressure gradient measurement vs. transjugular balloon occlusion measurement in patients with cirrhosis (ENCOUNTER): A bicentric EU study. JHEP Rep. 2025 May 29;7(8):101466. doi: 10.1016/j.jhepr.2025.101466. eCollection 2025 Aug.
PubMed 40689144Laleman W, Vanderschueren E, Mehdi ZS, Wiest R, Cardenas A, Trebicka J. Endoscopic procedures in hepatology: Current trends and new developments. J Hepatol. 2024 Jan;80(1):124-139. doi: 10.1016/j.jhep.2023.08.032. Epub 2023 Sep 18.
PubMed 37730125Vanderschueren E, Praktiknjo M, Wiest R, Cardenas A, Trebicka J, Laleman W. Recent advances in clinical practice endohepatology: the endoscopic liver rush. Gut. 2025 Oct 8;74(11):1916-1930. doi: 10.1136/gutjnl-2025-334725.
PubMed 40707208
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Inferior Vena Cava Pressure as Alternative to Hepatic Venous Pressure for EUS-guided Portal Pressure Gradient Measurement
- ClinicalTrials.gov ID
- NCT07703540
- Acronym / sponsor ID
- EUS-VEIN / MSPPG1
- Conditions
- Cirrhosis, Liver Disease Chronic, Portal Hypertension
- Keywords
- EUS-PPG, EUS, Portal hypertension, Portal vein pressure, Clinically significant portal hypertension (CSPH), Inferior vena cava pressure, Endoscopic ultrasound-guided portal pressure gradient
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- University Hospital MuensterUniversity, hospital or other
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 30 Apr 2026 (actual)
- Study completion
- 15 May 2026 (actual)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study investigates a new, simplified approach to measuring blood pressure within the liver (portal hypertension) using Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement (EUS-PPG). While this minimally invasive method traditionally relies on a hepatic vein as the baseline reference point, advanced liver scarring can make these veins twisted and highly difficult to access. To address this challenge, our study evaluates the Inferior Vena Cava (IVC)-the body's largest main vein-as an alternative reference site. Currently, it remains scientifically unproven whether the inferior vena cava or the hepatic vein provides the more reliable and accurate pressure reading for calculation, as anatomical distortion from cirrhosis can affect both areas differently. By measuring and comparing both venous compartments during a single, clinically scheduled endoscopy session, this study aims to determine if the pressures are truly interchangeable. Ultimately, this research will clarify which vessel serves as the optimal reference point, helping to establish a safer, more reliable diagnostic standard for patients with complex vascular anatomy.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| HVP-PPG and IVCP-PPG | – | Diagnostic Test: HVP-PPG and IVCP-PPGPatients undergoing both measurements (HVP-PPG and IVCP-PPG) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of consecutive adult patients ($\ge18$ years) undergoing a clinically indicated EUS-PPG measurement (e.g., for liver disease evaluation, fibrosis staging, or portal hypertension assessment).
Key inclusion criteria (1 listed)
- Consecutive adult patients (≥18 years) undergoing clinically indicated EUS-guided portal pressure gradient measurement
Key exclusion criteria (7 listed)
- severe coagulopathy (INR >2.0), thrombocytopenia (<50,000/µL)
- large-volume ascites
- gastric varices precluding safe vascular puncture
- known hepatic vein thrombosis or Budd-Chiari syndrome
- altered IVC anatomy such as patients after liver transplantation with piggy-back anastomosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HVP-PPG and IVCP-PPGDuring a clinically indicated endoscopic ultrasound (EUS), patients undergo portal pressure gradient (PPG) measurement using a linear-array echoendoscope and a dedicated needle system (22G or 25G). The intervention utilizes a transgastric approach to sequentially measure pressures in three vessels: a left intrahepatic portal vein branch, a hepatic vein, and the inferior vena cava (IVC). The IVC is safely punctured through a window covered by liver tissue. Pressures are measured in triplicate per vessel. This protocol uniquely calculates two distinct gradients within the same procedural session: HVP-PPG: Calculated as the mean portal vein pressure minus the mean hepatic vein pressure (HVP). IVCP-PPG: Calculated as the mean portal vein pressure minus the mean inferior vena cava pressure (IVCP). | Diagnostic test | HVP-PPG and IVCP-PPG |
Primary outcome
Agreement between mean hepatic vein pressure and mean inferior vena cava pressure measured during the same EUS-PPG session
Time frame: Intraprocedural
Based on prior reproducibility data for EUS-guided portal pressure measurements, a predefined absolute difference of >1 mmHg between HVP and IVCP was considered clinically relevant. Differences ≤1 mmHg after rounding to the nearest whole mmHg were considered hemodynamically equivalent, reflecting clinical pressure reporting practice.
5 secondary outcomes
Correlation between HVP and IVCP, Bland-Altman analysis of agreement and systematic bias
Time frame: Intraprocedural measurement
Agreement between PPG-HV and PPG-IVC
Time frame: Intraprocedural measurement
Reclassification across clinically significant portal hypertension thresholds (≥10 mmHg)
Time frame: Intraprocedural measurement
Intraprocedural variability of triplicate measurements
Time frame: Intraprocedural measurement
Procedural adverse events
Time frame: Up to 72 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Background: PubMed 40251984Santopaolo F, Giuli L, Tripodi G, Pallozzi M, Ponziani FR, Annicchiarico BE, Rizzatti G, Contegiacomo A, Posa A, Iezzi R, Talerico R, Gasbarrini A, Larghi A. Prognostic Role of Endoscopic Ultrasound Guided Direct Portal Pressure Gradient Measurement in Porto-Sinusoidal Vascular Disorder. Liver Int. 2025 May;45(5):e70096. doi: 10.1111/liv.70096.
- Background: PubMed 41046961Benmassaoud A, Bessissow A, Samoukovic G, Wong P, Zhao X, Deschenes M, Sebastiani G, Cabrera T, Valenti D, Boucher LM, Pelage JP, Muchantef K, Cardenas A, Givis MA, White S, Bousquet-Dion G, Waked C, Jacques J, Rahme E, Geraci O, Martel M, Barkun A, Maedler-Kron C, Chen YI. EUS-Guided Liver Biopsy and Portal Pressure Measurement Compared With a Transjugular Approach: A Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2026 Jun;24(6):1601-1610. doi: 10.1016/j.cgh.2025.09.025. Epub 2025 Oct 3.
- Background: PubMed 41748429Praktiknjo M, Farouk N, Wang Z, Stadtmann J, van de Loo D, Kimmann M, Gunia C, Meier JA, Uschner FE, Peiffer KH, Laleman W, Trebicka J, Braden B. Same Session Validation of a Custom-Built 22G With the Commercial 25G System for EUS-Guided Portal Pressure Gradient Measurement. United European Gastroenterol J. 2026 Mar;14(2):e70194. doi: 10.1002/ueg2.70194.
- Background: PubMed 32615178Zhang W, Peng C, Zhang S, Huang S, Shen S, Xu G, Zhang F, Xiao J, Zhang M, Zhuge Y, Wang L, Zou X, Lv Y. EUS-guided portal pressure gradient measurement in patients with acute or subacute portal hypertension. Gastrointest Endosc. 2021 Mar;93(3):565-572. doi: 10.1016/j.gie.2020.06.065. Epub 2020 Jun 29.
- Background: PubMed 27212121Rossle M, Blanke P, Fritz B, Schultheiss M, Bettinger D. Free Hepatic Vein Pressure Is Not Useful to Calculate the Portal Pressure Gradient in Cirrhosis: A Morphologic and Hemodynamic Study. J Vasc Interv Radiol. 2016 Aug;27(8):1130-7. doi: 10.1016/j.jvir.2016.03.028. Epub 2016 Jun 7.
- Background: PubMed 26238376Silva-Junior G, Baiges A, Turon F, Torres F, Hernandez-Gea V, Bosch J, Garcia-Pagan JC. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology. 2015 Nov;62(5):1584-92. doi: 10.1002/hep.28031. Epub 2015 Sep 30.
- Background: PubMed 38945633Rodrigues SG, Delgado MG, Stirnimann G, Berzigotti A, Bosch J. Hepatic Venous Pressure Gradient: Measurement and Pitfalls. Clin Liver Dis. 2024 Aug;28(3):383-400. doi: 10.1016/j.cld.2024.03.009. Epub 2024 May 1.
- Background: PubMed 759258Groszmann RJ, Glickman M, Blei AT, Storer E, Conn HO. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology. 1979 Feb;76(2):253-8.
- Background: PubMed 32628153Reiberger T, Schwabl P, Trauner M, Peck-Radosavljevic M, Mandorfer M. Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. J Vis Exp. 2020 Jun 18;(160). doi: 10.3791/58819.
- Background: PubMed 40901597Singla N, Shantan V, Saraswat A, Singh AP. Advances in portal pressure measurement: Endoscopic techniques, challenges, and implications for liver transplantation. World J Hepatol. 2025 Aug 27;17(8):107679. doi: 10.4254/wjh.v17.i8.107679.
- Background: PubMed 38779643Dhindsa BS, Tun KM, Fiedler A, Deliwala S, Saghir SM, Scholten K, Ramai D, Girotra M, Chandan S, Dhaliwal A, Bhat I, Singh S, Adler DG. Endoscopic ultrasound-guided portal pressure gradient measurement: a systematic review and meta-analysis. Ann Gastroenterol. 2024 May-Jun;37(3):356-361. doi: 10.20524/aog.2024.0882. Epub 2024 Apr 29.
- Background: PubMed 39025130Martinez-Moreno B, Martinez Martinez J, Herrera I, Guilabert L, Rodriguez-Soler M, Bellot P, Miralles C, Pascual S, Irurzun J, Zapater P, Palazon-Azorin JM, Gil Guillen V, Jover R, Aparicio JR. Correlation of endoscopic ultrasound-guided portal pressure gradient measurements with hepatic venous pressure gradient: a prospective study. Endoscopy. 2025 Jan;57(1):62-67. doi: 10.1055/a-2369-0759. Epub 2024 Jul 18.
- Individual participant dataSharing planned: No
Related trials for Cirrhosis
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
Recruiting
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous Bacterial Peritonitis, Paracentesis
RecruitingObservational study
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices
Recruiting
CirrhosisRx CDS System
Cirrhosis, Decision Support Systems, Clinical
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cirrhosis and Liver Disease Chronic, run by University Hospital Muenster at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Agreement between mean hepatic vein pressure and mean inferior vena cava pressure measured during the same EUS-PPG session (time frame: Intraprocedural). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07703540, which also lists 19 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.